Lupin–Yabao partnership to bring paediatric medicines to China

INICIO/Noticias Farmacéuticas | Posted 20/05/2022 post-comment0 Post your comment

In April 2022, global pharmaceutical company, Lupin announced that it has entered a strategic partnership with China’s Yabao Pharmaceutical Company. Together, the companies will work to meet the growing demand for quality drugs with paediatric formulations in Chinese markets.

71 MD002166

China has a growing demand for paediatric formulations which is bolstered by the government’s support and policy measures. It has been reported that the market for paediatric drugs in China was expected to reach US$33 billion US in 2021, growing at a rate of just under 10%. With this new collaboration, Lupin hopes to access this burgeoning Chinese paediatrics market.

The collaboration also enables Lupin to take advantage of Yabao’s fully integrated development, manufacturing, and commercialization processes in China. In addition to marketing paediatric formulations in China, Lupin hopes to expand the collaboration with Yabao in other strategic therapeutics areas such as cardio-metabolic, central nervous system and gastroenterology.

Lupin has entered a number of strategic partnerships in other regions of the world [1, 2], however, this is the first specifically focused on bringing paediatric formulations to market.

Related articles
FDA accepts application for Lupin’s pegfilgrastim biosimilar

Lupin to sell its Japanese arm and Sandoz to acquire Aspen’s Japanese business

Lupin to sell Japanese injectables business and collaborates with German drugmaker on anticancer treatment


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Nomenclature of biologicals and biosimilars in Peru

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Nomenclature of biologicals and biosimilars in Peru

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Axantia to market Lupin’s pegfilgrastim in the Middle East and North Africa []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 May 20]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Lupin forms partnership to market pegfilgrastim biosimilar in Brazil []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 May 20]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
El recorrido del biológico de continuación Pectuna (pertuzumab) en Irán
Cancer Cell V13I20
INICIO/Noticias Farmacéuticas Posted 29/02/2024
Fiocruz y Pfizer firman un acuerdo para el genérico de Xeljanz
Remicade V13F28
INICIO/Noticias Farmacéuticas Posted 30/01/2024
Genfar: La nueva marca de genéricos de Eurofarma en América Latina
10 AA008993
INICIO/Noticias Farmacéuticas Posted 12/12/2023
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010